Innova Captab Limited (INNOVACAP) - Total Liabilities
Based on the latest financial reports, Innova Captab Limited (INNOVACAP) has total liabilities worth Rs7.47 Billion INR (≈ $80.74 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Innova Captab Limited liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Innova Captab Limited - Total Liabilities Trend (2018–2026)
This chart illustrates how Innova Captab Limited's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see balance sheet size of Innova Captab Limited.
Innova Captab Limited Competitors by Total Liabilities
The table below lists competitors of Innova Captab Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Propel Holdings Inc
TO:PRL
|
Canada | CA$379.99 Million |
|
China Hi-Tech Group Co Ltd
SHG:600730
|
China | CN¥231.83 Million |
|
Changzhou Galaxy Century Microelectronics Co Ltd
SHG:688689
|
China | CN¥921.14 Million |
|
Center Laboratories
TWO:4123
|
Taiwan | NT$6.17 Billion |
|
Huachangda Intelligent Equipment Group Co Ltd
SHE:300278
|
China | CN¥1.82 Billion |
|
Shenzhen Xinhao Photoelectricity Technology Co. Ltd
SHE:301051
|
China | CN¥1.67 Billion |
|
Vestis Corporation
NYSE:VSTS
|
USA | $2.15 Billion |
|
SENORES PHARMACEUTICALS L
NSE:SENORES
|
India | Rs6.39 Billion |
Liability Composition Analysis (2018–2026)
This chart breaks down Innova Captab Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See INNOVACAP equity financing ratio to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.87 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.68 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.41 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Innova Captab Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Innova Captab Limited (2018–2026)
The table below shows the annual total liabilities of Innova Captab Limited from 2018 to 2026.
| Year | Total Liabilities | Change |
|---|---|---|
| 2026-03-31 | Rs7.47 Billion ≈ $80.74 Million |
+20.23% |
| 2025-03-31 | Rs6.21 Billion ≈ $67.16 Million |
+26.74% |
| 2024-03-31 | Rs4.90 Billion ≈ $52.99 Million |
-29.31% |
| 2023-03-31 | Rs6.93 Billion ≈ $74.96 Million |
+88.93% |
| 2022-03-31 | Rs3.67 Billion ≈ $39.68 Million |
+63.20% |
| 2021-03-31 | Rs2.25 Billion ≈ $24.31 Million |
+131359.06% |
| 2020-03-31 | Rs1.71 Million ≈ $18.49K |
-99.94% |
| 2019-03-31 | Rs2.98 Billion ≈ $32.23 Million |
+113.03% |
| 2018-03-31 | Rs1.40 Billion ≈ $15.13 Million |
-- |
About Innova Captab Limited
Innova Captab Limited, an integrated pharmaceutical company, engages in the research and development, manufacture, distribution, and marketing of drugs in India and internationally. The company provides contract development and manufacturing organization services to Indian pharmaceutical companies. It is also offers various generic formulation products, including cephalosporins, proton pump inhib… Read more